Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 7/20 | 0.53 |
| ▸ | CBFB | Q13951 | 1/20 | 0.50 |
| ▸ | NPBWR1 | P48145 | 5/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5214652 | 0.92 | KIT (0.52) | KITCBFBNPBWR1OPRM1 | |
| SCHEMBL5213900 | 0.88 | KIT (0.54) | KITCBFBNPBWR1DGAT1KCNH2 | |
| SCHEMBL5219975 | 0.80 | CBFB (0.54) | KITCBFBNPBWR1DGAT1KCNH2 | |
| SCHEMBL14422260 | 0.77 | KIT (0.45) | KITCBFBNPBWR1 | |
| SCHEMBL5221536 | 0.74 | CBFB (0.51) | KITCBFBNPBWR1DGAT1KCNH2 | |
| SCHEMBL6176583 | 0.73 | CBFB (0.42) | KITCBFBNPBWR1DGAT1KCNH2 | |
| SCHEMBL14422259 | 0.73 | MEN1 (0.50) | KITCBFBNPBWR1DGAT1KCNH2 | |
| SCHEMBL5219967 | 0.72 | KIT (0.47) | KITCBFBDYRK1ADYRK1B | |
| SCHEMBL17782853 | 0.71 | KIT (0.70) | KIT | |
| SCHEMBL17782817 | 0.70 | KIT (0.77) | KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265138-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1818333-A1 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| EP-1603905-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004072068-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| US-20040157845-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157845-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | KIT 266/4885CBFB 1560/4885NPBWR1 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.